IL2 and neoplasm: High cure rate was not seen with i.t. NJT6-IL2, or with intravenous delivery of any of the nanobody-IL2 fusions, suggesting that both affinity to the tumor ECM and i.t. administration can together maximize antitumor benefit from small-format (∼32 kDa) IL-2 immunocytokines.